Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 50.77M P/E - EPS this Y - Ern Qtrly Grth -
Income -10.31M Forward P/E -1.70 EPS next Y -2.10% 50D Avg Chg 45.00%
Sales 3.73M PEG - EPS past 5Y - 200D Avg Chg 102.00%
Dividend N/A Price/Book 3.19 EPS next 5Y - 52W High Chg -40.00%
Recommedations 1.50 Quick Ratio 5.22 Shares Outstanding 8.92M 52W Low Chg 761.00%
Insider Own 12.20% ROA -40.87% Shares Float 6.76M Beta 1.55
Inst Own 22.65% ROE -71.74% Shares Shorted/Prior 83.82K/98.55K Price 5.77
Gross Margin -156.82% Profit Margin -278.22% Avg. Volume 861,779 Target Price 11.75
Oper. Margin -197.40% Earnings Date Nov 7 Volume 217,337 Change 4.72%
About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Marker Therapeutics, Inc. News
08/28/24 Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
08/14/24 Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
08/12/24 Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
07/18/24 Marker Therapeutics (NASDAQ:MRKR) shareholders are up 20% this past week, but still in the red over the last five years
05/15/24 Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
04/08/24 Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
03/25/24 Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
03/22/24 Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
01/22/24 Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
01/08/24 Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
01/08/24 Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
12/21/23 Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
12/11/23 Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
11/09/23 Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
10/11/23 Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
MRKR Chatroom

User Image Americanbulls Posted - 10 hours ago

$MRKR the bull pattern is confirmed & a BUY signal is issued @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=MRKR. Buy Level: 2.91 Target: 3.78

User Image GiamIsBack Posted - 1 day ago

$MRKR

User Image Americanbulls Posted - 3 days ago

$MRKR may go up 30% if the bull pattern is confirmed. Check confirmation [50%] @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=MRKR. Buy level:2.88.

User Image GiamIsBack Posted - 6 days ago

$MRKR

User Image My74Nova Posted - 6 days ago

$MRKR I put an order in @ $2.50 (GTC), that should keep the price above $2.50.

User Image itsMeRich Posted - 1 week ago

$MRKR looking like failed study results are leaking out to the big boys….

User Image RallyRaider Posted - 1 week ago

$MRKR was up on 500 shares and no one immediately corrected it now 4k shares.... stoopid chasers? or something in the works

User Image GiamIsBack Posted - 1 week ago

$MRKR

User Image Aigner_Andreas Posted - 1 week ago

#DeathCross $MRKR at 3.08 R16 HiLo 19% T1Y 2 buy 2.3 DIV N/A #Marker The #stocks #trading #finance #market

User Image MRKR2025 Posted - 1 week ago

$MRKR I have owned this stock for about a quarter of a century back to when it was Tapimmune TPIV, that is more than 1/3 of my life. It is and has been one of my largest investments, my average cost is mid teens and needless to say, it has not performed very well. Back at under $3 again, I would like to say: HELPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPPP

User Image GiamIsBack Posted - 1 week ago

$MRKR

User Image My74Nova Posted - 2 weeks ago

$MRKR typical after I buy...

User Image MRKR2025 Posted - 2 weeks ago

$MRKR Low $3's again, again, again, GEEZ, GEEZ AGAIN.

User Image GiamIsBack Posted - 2 weeks ago

$MRKR shit is going down!

User Image itsMeRich Posted - 08/29/24

$MRKR up .40 on 396 shares🤣🤣🤣 When they announce that their treatment makes CAR-T a treatment of the past- this will probably run to $200 in a day!

User Image BioRich Posted - 08/23/24

$TNXP remember this was trading above 50 cents/share before the Kamala Market Crash Monday a few weeks ago. That's almost 50% bump from where we sit now. Since then? Monkey pox play possibilities and initiated their Phase II dosing in one of their trials. This is EXTREMELY undervalued. Even without Monkey Pox, this has easy 5x potential within months. Check out $XFOR, $NRSN, $GUTS and $MRKR if you're the type that likes to research and make money. Follow/Subscribe for more tips and suggestions. Would love to hear yours too. Let's make some money. Cheers!

User Image GiamIsBack Posted - 08/22/24

$MRKR

User Image Himel92 Posted - 1 month ago

The Last month Performance for $MRKR Opening Price: $5.13 Closing Price: $3.49 Highest Price: $5.62 Lowest Price: $3.15 Percentage Change: -31.97% Data analyst: AITX

User Image RallyRaider Posted - 1 month ago

$MRKR watch out 15k follower account commented maybe in more groups too

User Image Mrs_BlackINKEconomics Posted - 1 month ago

$MRKR 🤔 bullish techs…

User Image epsguid Posted - 1 month ago

$MRKR reported a loss of $0.25 via @eWhispers http://eps.sh/d/mrkr

User Image Stock_Titan Posted - 1 month ago

$MRKR Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates https://www.stocktitan.net/news/MRKR/marker-therapeutics-reports-second-quarter-2024-financial-results-utgwa9q9oau7.html

User Image itsMeRich Posted - 1 month ago

$MRKR can this really drop into the $2’s? We need news - and soon!

User Image MRKR2025 Posted - 1 month ago

$MRKR 2 questions: WHY? and WTF?

User Image RallyRaider Posted - 1 month ago

$MRKR 10q due

User Image MRKR2025 Posted - 1 month ago

$MRKR They get a free 2 million ... and it goes down ???

User Image BioTuesdays Posted - 1 month ago

Marker Therapeutics has announced that it has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with non-Hodgkin’s lymphoma (NHL) $MRKR https://biotuesdays.com/2024/08/12/nih-awards-grant-to-marker-therapeutics-through-sbir-program/

User Image Finanz Posted - 1 month ago

$MRKR Good news for Marker being awarded a $2 million grant from the NIH Small Business Innovation Research (SBIR) program. Better to have a grant than a dilutive capital raise to finance their Phase 1 APOLLO study, investigating the safety and efficacy of MT-601 in patients with non-Hodgkin’s lymphoma who have relapsed following anti-CD19 CAR-T cell therapy. Including this NIH SBIR grant, Marker has been awarded over $19 million in non-dilutive funding proceeds. More to come?

User Image MRKR2025 Posted - 1 month ago

$MRKR Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-awarded-2-million-grant-nih-support-phase-1

User Image Stocks4thought Posted - 1 month ago

$MRKR Passed on ATM- one could assume they new data will be good and get a premium vs a discount. If you needed cash in tight markets (SVB failure)- You'd embraced the oppty for cap raise?

Analyst Ratings
Ladenburg Thalmann Buy Apr 30, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Eansor Norman David Director Director Mar 16 Buy 17.5 14,285 249,988 16,713 06/08/23